ConvaTec Group PLC

Chart & Performance

D1W1MN

P/E

4,311.21

P/S

262.21

EPS

0.06

Div Yield, %

0.02%

Shrs. gr., 5y

0.95%

Rev. gr., 5y

3.18%

Revenues

2.14b

+3.37%

Net income

130m

+107.15%

CFO

367m

+30.42%

Dividend

Aug 22, 20241.0763 GBP/sh

Earnings

Mar 04, 2025

Profile

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

URL

https://www.convatecgroup.com/

IPO date

Oct 26, 2016

Employees

10,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	2,142,400 3.37%	2,072,500 1.68%	2,038,300 7.60%
Cost of revenue	1,859,500	1,817,800	1,808,300
Unusual Expense (Income)
NOPBT	282,900	254,700	230,000
NOPBT Margin	13.20%	12.29%	11.28%
Operating Taxes	37,100	19,000	33,700
Tax Rate	13.11%	7.46%	14.65%
NOPAT	245,800	235,700	196,300
Net income	130,300 107.15%	62,900 -46.51%	117,600 4.53%
Dividends	(110,700)	(88,100)	(85,800)
Dividend yield	2.21%	1.86%	2.19%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	20,700	20,300	164,500
Long-term debt	1,377,200	1,300,500	1,293,200
Deferred revenue		1,129,000	1,115,500
Other long-term liabilities	192,900	(1,212,200)	(1,202,700)
Net debt	1,276,700	1,144,100	(1,483,700)
Cash flow
Cash from operating activities	367,400	281,700	305,900
CAPEX	(129,200)	(144,200)	(94,100)
Cash from investing activities	(285,700)	(348,300)	(206,500)
Cash from financing activities	(124,000)	(237,100)	(199,900)
FCF	95,000	216,200	147,600
Balance
Cash	98,300	145,800	463,400
Long term investments	22,900	30,900	2,478,000
Excess cash	14,080	73,075	2,839,485
Stockholders' equity	(637,200)	1,445,500	1,554,700
Invested Capital	3,835,200	2,863,425	1,552,900
ROIC	7.34%	10.67%	12.42%
ROCE	8.85%	8.43%	7.20%
EV
Common stock shares outstanding	2,052,589	2,040,247	2,026,340
Price	2.44 4.99%	2.33 20.42%	1.93 -3.04%
Market cap	5,012,423 5.62%	4,745,616 21.25%	3,913,876 -2.08%
EV	6,289,123	5,889,716	2,430,176
EBITDA	497,700	450,800	426,900
EV/EBITDA	12.64	13.07	5.69
Interest	73,300	64,700	36,200
Interest/NOPBT	25.91%	25.40%	15.74%